Director at Tectonic Therapeutic (TECX) receives 10,200 stock options expiring 2036

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. director Stefan Vitorovic received a grant of stock options covering 10,200 shares of common stock. The options have an exercise price of $28.56 per share and expire on June 8, 2036, bringing his option holdings to 10,200 shares.

According to the terms, the award vests in full on the earliest of June 9, 2027, the company’s 2027 annual stockholder meeting, or a qualifying change in control, in each case only if he continues providing service to the company through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vitorovic Stefan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,200	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 10,200 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 10,200 options Exercise price: $28.56 per share Expiration date: June 8, 2036 +3 more

6 metrics

Options granted 10,200 options Stock Option (Right to Buy) grant on June 9, 2026

Exercise price $28.56 per share Conversion or exercise price for granted options

Expiration date June 8, 2036 Option expiration if not exercised earlier

Post-grant holdings 10,200 options Total derivative securities owned following transaction

Transaction code A (grant/award acquisition) Indicates compensation-related option grant

Vesting timing Earliest of June 9, 2027, 2027 meeting, or change in control Subject to continuous service requirement

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Change in Control, 2024 Equity Incentive Plan, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Change in Control financial

"or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

2024 Equity Incentive Plan financial

"as defined in the Issuer's 2024 Equity Incentive Plan"

continuous service financial

"subject in each case, to the Reporting Person providing continuous service to the Issuer"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/10/2026 - 04:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vitorovic Stefan

(Last)

(First)

(Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$28.56	06/09/2026		A		10,200		⁽¹⁾	06/08/2036	Common Stock	10,200	$0	10,200	D

Explanation of Responses:

1. The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

	/s/ Daniel Lochner, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Tectonic Therapeutic (TECX) director Stefan Vitorovic report on this Form 4?

Director Stefan Vitorovic reported receiving a grant of stock options for 10,200 shares of Tectonic Therapeutic common stock. These options were awarded at no cost, have an exercise price of $28.56 per share, and represent 10,200 options held after the transaction.

What are the key terms of the 10,200 stock options granted to the TECX director?

The grant consists of options to buy 10,200 shares of common stock at an exercise price of $28.56 per share. The options are scheduled to expire on June 8, 2036, if not exercised earlier, according to the reported terms.

When do Stefan Vitorovic’s Tectonic Therapeutic (TECX) options vest?

The options vest in full on the earliest of June 9, 2027, the date of Tectonic Therapeutic’s 2027 annual meeting of stockholders, or a qualifying change in control, provided he continues to serve the company through the applicable vesting date.

How many Tectonic Therapeutic (TECX) options does the director hold after this grant?

Following this transaction, the director holds options covering 10,200 shares of Tectonic Therapeutic common stock. The filing shows this as the total number of derivative securities beneficially owned after the reported grant on the transaction date.

What type of transaction is reported in this Tectonic Therapeutic (TECX) Form 4?

The Form 4 reports a derivative transaction coded “A,” indicating a grant, award, or other acquisition of stock options. It reflects a compensation-related award rather than an open-market purchase or sale of Tectonic Therapeutic common shares.

What conditions affect vesting of the TECX stock options granted to the director?

Vesting requires continuous service with Tectonic Therapeutic until the earliest of June 9, 2027, the 2027 annual stockholder meeting date, or a defined change in control under the company’s 2024 Equity Incentive Plan, based on the filing’s footnote.